The oral solution offers precise dosing, benefiting patients with swallowing difficulties or requiring tailored dosing.

Of the compounds Nick sent me for testing, I identified CGP 57148B (also known as STI571, Gleevec, Glivec or imatinib mesylate) as the most effective at killing CML cells without harming normal ...

Imkeldi is a new formulation of imatinib approved as a strawberry-flavored, shelf-stable liquid designed to be more appealing ...

This overexpression suggested that imatinib could be clinically applicable in uveal melanoma metastases; this was tested in a group of patients who were assigned to receive imatinib 600 mg daily ...

Imatinib oral solution has gained FDA approval for the treatment of some cancers, including certain forms of leukemia.

FDA has approved imatinib (IMKELDI), the first oral liquid tyrosine kinase inhibitor for treating leukemia and a range of cancers, including CML, GIST, and Ph+ ALL. Developed by Shorla Oncology ...

In 2001, a Time Magazine cover story touted Novartis’ targeted leukemia treatment Gleevec (imatinib) as a new kind of ...

Imkeldi is a liquid formulation of imatinib that utilizes proprietary technology to allow for accurate dosing and an alternative formulation to tablets.

Shilpa Medicare’s Joint Venture Oncosol along with its partner Shorla Oncology announces that the USFDA has approved IMKELDI ...

News on Inhibikase's promising treatments for PAH and Parkinson's Disease, supported by FDA approval and substantial funding.

The US Food and Drug Administration (FDA) has approved Imkeldi (imatinib) oral solution, the first oral liquid form of ...

Shilpa Medicare's Joint Venture Oncosol, along with its partner Shorla Oncology, on Wednesday announced that the US FDA has ...